RESPIRATORY SYNCYTIAL VIRUS AND CHILD PNEUMONIA WEBINAR

Listen to talks by:
  • Dr. Ting Shi (University of Edinburgh): Global disease burden estimate of RSV in young children
  • Dr. Marijke Proesmans (Katholieke Universiteit Leuven): RSV therapeutics
  • Dr. Keith Klugman (Director, Pneumonia, Bill&Melinda Gates Foundation): RSV immunization and future directions
  • Dr. Louis Bont (Chairman ReSViNET Foundation): RSV clinical presentation and disease severity
Visual
Use the link below to access the SlideShare presentation for the talks:
https://www.slideshare.net/secret/H0MzMgF2seNUX7
 NOTE: Please download this slide deck from the SlideShare platform to view.

Recent RESVINET PUBLICATIONs

EXPERT CONSENSUS ON PALIVIZUMAB USE FOR RESPIRATORY SYNCYTIAL VIRUS IN DEVELOPED COUNTRIES
Sánchez Luna M, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, Resch B, Carbonell-Estrany X.
Abstract
Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to costs-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. ..read more

Educational activities

PeerVoice has launched three RSV activities, in collaboration with and endorsed by ReSViNET Foundation. Use the link below for more information and content of the programs.

Upcoming Conference

On 12- 14 November 2019 ReSViNET Foundation will host its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. ​
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. 
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.

ABOUT RESVINET FOUNDATION

PAPER OF THE MONTH

The endangered future of Syngem, a novel bacterium-like particle based, needle-free, RSV vaccine
Ascough S, Vlachantoni I, Kalyan M, Haijema BJ, Wallin- Weber S, Dijkstra-Tiekstra M, Ahmed MS, Roosmalen M van, Grimaldi R, Zhang Q, Leenhouts K, Openshaw PJ and Chiu C.

Despite numerous years of research we are still lacking a safe and effective RSV vaccine. This process is hindered by numerous problems: the lack of a correlate of protection being one of them.That this has major consequences for vaccine development, is illustrated by the study performed by Stephanie Ascough, Peter Openshaw and colleagues. In their paper they describe the results of a randomized controlled, phase 1 trial of a novel needle-free RSV vaccine: SynGEM. The vaccine is based on a stable pre-fusion F antigen of the virus, and uses a bacterium-like-particle (BLP) as an immune-enhancing carrier. The study confirms that the vaccine is safe and that it is capable of inducing a mild (about 2 to 3-fold), but prolonged, increase in RSV-specific antibodies. However, the study didn’t reach the endpoint threshold and for now, SynGEM is withheld from proceeding to next phase trials.
This study illustrates, that the lack of a correlate of protection brings an uncertainty to the table, which could lead to the premature termination of a potentially effective RSV vaccine. The use of a human challenge model (HCM) in RSV vaccine development would offer the possibility to circumvent this insecurity. Furthermore it might accelerate RSV-vaccine development.
Written by Sjanna Besteman

ReSViNET Global partners